|

Investigator's choice of chemotherapy Clinical Trials

5 actively recruiting trials across 3 locations

▲ +1 trial since May 2026

Also known as: GemNabP, ICC, gemcitabine, mFOLFIRINOX, paclitaxel +2 more

Pipeline

Phase 2: 1Phase 3: 4

Top Sponsors

  • Incyte Corporation2
  • K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc1
  • Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.1
  • Fudan University1

Indications

Other2 trials

A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations
Phase 2
Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype
Phase 3

Birmingham, Alabama1 trial

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

Investigative Site US058

Phase 3

Anchorage, Alaska1 trial

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Alaska Womens Cancer Care Akwcc

Phase 3

Phoenix, Arizona1 trial

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

Site 0107

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.